RG108 treatment increases the expression of anti-senescence genes, while p53 and p16 expressions are suppressed, in ALS patient-derived bone marrow mesenchymal stromal cells [111]; in addition, RG108 treatment of mice can activate the rejuvenation stemness gene hes5 [112]. Here, HES5 is linked to amyotrophic lateral sclerosis.